Otsuka Pharmaceutical
↗Chiyoda, Tokyo, Japan
Otsuka Pharmaceutical is a major global pharmaceutical company with a century of heritage, founded in 1921 and headquartered in Tokyo, Japan. The company is a subsidiary of Otsuka Holdings Co., Ltd., a diversified healthcare company that operates through pharmaceuticals, medical nutrition, and consumer products divisions. Otsuka Pharmaceutical operates worldwide with over 35,000 employees and generates approximately $16 billion in annual revenue. The company focuses on developing innovative therapies across psychiatry, neurology, oncology, and cardiovascular/renal disease areas, with a strong commitment to addressing unmet medical needs. Otsuka has established itself as a leader in psychiatric medications while simultaneously building oncology capabilities through acquisitions and strategic partnerships.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Psychiatry, Neurology, Oncology, Renal/Cardiovascular
SIZE & FINANCIALS
Employees:10000+
Revenue:$16B annual revenue (TTM: $14.47B)
Founded:1921
Ownership:public
Status:operating
FUNDING
Stage:Public/Mature
STOCK
Exchange:Tokyo Stock Exchange
Ticker:4578.T (Otsuka Holdings); OTSKY/OTSKF (ADR in US)
Market Cap:$25.8B
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial/Recently Approved
Modalities:Small molecule, mAb (monoclonal antibodies), Injectable/Depot formulations, Digital therapeutics, Biologics
Active Trials:903
Trial Phases:Phase 1: 120 | Phase 2: 280 | Phase 3: 340 | Phase 4: 163
FDA Approvals:15
EMA Approvals:12
CORPORATE STRUCTURE
Parent Company:Otsuka Holdings Co., Ltd.
Subsidiaries:Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd. (Oncology), Astex Pharmaceuticals (Cambridge, UK - Oncology/Fragment-based drug discovery), Visterra Inc. (Boston, MA - Immunology), Jnana Therapeutics (Boston, MA - Autoimmune, acquired 2024), Mindset Pharma (acquired 2023), Otsuka America, Inc., Otsuka Chemical Co., Ltd., Otsuka Warehouse Co., Ltd.
Key Partnerships:Lundbeck, Visterra Inc., Sumitomo Pharma, Cullinan Therapeutics
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical (Japan's #1 pharma by sales), Eli Lilly (psychiatry, Alzheimer's), Janssen/J&J (psychiatry, including paliperidone competitors), Bristol-Myers Squibb (former Abilify co-owner via Bristol-Myers acquisition), AbbVie (psychiatry drugs), Lundbeck (psychiatry partner/competitor), Amgen (renal disease), Roche (IgAN and oncology) +2 more
LEADERSHIP
Key Executives:
Makoto Inoue - Director, President & CEO (Otsuka Holdings)
Ichiro Otsuka - Chairman (Otsuka Holdings)
Yuko Makino - CFO & Director (Otsuka Holdings)
Tarek Rabah - President & CEO, North America Pharmaceutical Business
Scientific Founders:Busaburo Otsuka, Masahito Otsuka
Board Members:Ichiro Otsuka (Chairman), Makoto Inoue (CEO), Yuko Makino (CFO/Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Otsuka Pharmaceutical. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.